Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up – Still a Buy?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) gapped up before the market opened on Friday . The stock had previously closed at $25.61, but opened at $26.42. Dyne Therapeutics shares last traded at $25.71, with a volume of 40,896 shares.

Analyst Ratings Changes

Several analysts have commented on the stock. Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a report on Friday. They set an “outperform” rating and a $46.00 target price on the stock. Royal Bank of Canada initiated coverage on shares of Dyne Therapeutics in a report on Tuesday, November 26th. They set an “outperform” rating and a $45.00 price objective on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Chardan Capital reiterated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $50.42.

Dyne Therapeutics Stock Up 0.5 %

The company’s 50 day moving average is $30.39 and its 200 day moving average is $35.23. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of -7.23 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Insider Buying and Selling

In related news, SVP Richard William Scalzo sold 1,390 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the transaction, the senior vice president now owns 98,568 shares in the company, valued at $3,405,524.40. The trade was a 1.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jason P. Rhodes sold 782 shares of the stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $33.10, for a total value of $25,884.20. Following the sale, the director now owns 15,962 shares of the company’s stock, valued at approximately $528,342.20. The trade was a 4.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 180,046 shares of company stock valued at $6,300,265 over the last 90 days. 20.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its position in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the period. Quantbot Technologies LP acquired a new position in Dyne Therapeutics during the third quarter worth $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics in the third quarter valued at $36,000. US Bancorp DE lifted its stake in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of Dyne Therapeutics during the third quarter valued at about $62,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.